Invention Grant
- Patent Title: Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
-
Application No.: US16875573Application Date: 2020-05-15
-
Publication No.: US11382860B2Publication Date: 2022-07-12
- Inventor: Roland Greinwald , Ralph Mueller , Markus Proels , Rudolf Wilhelm
- Applicant: Dr. Falk Pharma GmbH
- Applicant Address: DE Freiburg
- Assignee: Dr. Falk Pharma GmbH
- Current Assignee: Dr. Falk Pharma GmbH
- Current Assignee Address: DE Freiburg
- Agency: Smith Patent, LLC
- Agent Chalin A. Smith
- Priority: EP13199278 20131223
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K9/46 ; A61K31/58 ; A61K9/20

Abstract:
Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
Public/Granted literature
- US20200337997A1 OPTIMIZED PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE ESOPHAGUS Public/Granted day:2020-10-29
Information query